{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:40:16Z","timestamp":1794271216924,"version":"4.9.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment-resistant depression (TRD) continues to pose a major challenge in clinical practice, as a large proportion of patients fail to achieve remission despite multiple antidepressant drugs. Growing evidence indicates that dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, together with epigenetic alterations, neuroinflammation, and kynurenine pathway metabolism, plays a central role in the pathophysiology of TRD. Particularly, prolonged stress-induced glucocorticoid receptor (GR) resistance, persistent hypercortisolaemia, and elevated pro-inflammatory cytokines contribute to neurotoxicity, hippocampal atrophy, and impaired neuroplasticity, aggravating depressive symptoms and reducing treatment response. Additionally, dysregulated tryptophan metabolism and the shift towards neurotoxic kynurenine metabolites further impair neuronal function and resulting in TRD. This review integrates recent findings on the complex interplay between HPA axis dysfunction, neuroimmune responses, and metabolic disturbances in TRD while highlighting novel therapeutic avenues such as ketamine, GR modulators, and anti-inflammatory agents. Further, disruption in the blood-brain barrier as one of the mechanisms of TRD was also reviewed. A deeper understanding of these mechanisms will enable the development of personalized treatment strategies to enhance clinical outcomes for TRD patients.<\/jats:p>","DOI":"10.1007\/s43440-025-00806-6","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:52:22Z","timestamp":1763531542000},"page":"374-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The HPA axis and kynurenine pathway: exploring the role of stress and neuroinflammation in treatment-resistant depression"],"prefix":"10.1007","volume":"78","author":[{"given":"Madhura M.","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Govindula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavan","family":"Nampoothiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-7769","authenticated-orcid":false,"given":"Devinder","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-7031","authenticated-orcid":false,"given":"Jayesh","family":"Mudgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"806_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340. https:\/\/doi.org\/10.1176\/appi.ajp.163.1.28.","journal-title":"Am J Psychiatry"},{"key":"806_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s10578-021-01231-5","volume":"54","author":"G Serafini","year":"2023","unstructured":"Serafini G, Aguglia A, Amerio A, Canepa G, Adavastro G, Conigliaro C, et al. The relationship between bullying victimization and perpetration and non-suicidal self-injury: a systematic review. Child Psychiatry Hum Dev. 2023;54:154\u201375. https:\/\/doi.org\/10.1007\/s10578-021-01231-5.","journal-title":"Child Psychiatry Hum Dev"},{"key":"806_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/da.22865","volume":"36","author":"van Dijk DA","year":"2019","unstructured":"van Dijk DA, van den Boogaard TM, Deen ML, Spijker J, Ruh\u00e9 HG, Peeters FPML . Predicting clinical course in major depressive disorder: the association between DM-TRD score and symptom severity over time in 1115 outpatients. Depress Anxiety. 2019;36:345\u201352. https:\/\/doi.org\/10.1002\/da.22865.","journal-title":"Depress Anxiety"},{"key":"806_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.17352\/2455-5460.000038","volume":"5","author":"G Perrotta","year":"2019","unstructured":"Perrotta G. Depressive disorders: definitions, contexts, differential diagnosis, neural correlates and clinical strategies. Arch Depress Anxiety. 2019;5:9\u201333. https:\/\/doi.org\/10.17352\/2455-5460.000038.","journal-title":"Arch Depress Anxiety"},{"key":"806_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.24869\/psyd.2018.273","volume":"30","author":"JP Pandarakalam","year":"2018","unstructured":"Pandarakalam JP. Challenges of treatment-resistant depression. Psychiatr Danub. 2018;30:273\u201384. https:\/\/doi.org\/10.24869\/psyd.2018.273.","journal-title":"Psychiatr Danub"},{"key":"806_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.neubiorev.2017.08.019","volume":"84","author":"H Akil","year":"2018","unstructured":"Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272\u201388. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.08.019.","journal-title":"Neurosci Biobehav Rev"},{"key":"806_CR7","doi-asserted-by":"publisher","first-page":"100331","DOI":"10.1016\/j.bbih.2021.100331","volume":"16","author":"L Sforzini","year":"2021","unstructured":"Sforzini L. Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression. Brain Behav Immun Health. 2021;16:100331. https:\/\/doi.org\/10.1016\/j.bbih.2021.100331.","journal-title":"Brain Behav Immun Health"},{"key":"806_CR8","doi-asserted-by":"publisher","unstructured":"Malley S, Tanaka H. Pharmacological management of treatment-resistant depression: current approaches and future directions. Arch Clin Psychiatry. 2023;50. https:\/\/doi.org\/10.15761\/0101-60830000000526.","DOI":"10.15761\/0101-60830000000526"},{"key":"806_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/11530280-000000000-00000","volume":"24","author":"RC Shelton","year":"2010","unstructured":"Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24:131\u201361. https:\/\/doi.org\/10.2165\/11530280-000000000-00000.","journal-title":"CNS Drugs"},{"key":"806_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369\u201388. https:\/\/doi.org\/10.2147\/PPA.S29716.","journal-title":"Patient Prefer Adherence"},{"key":"806_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.v66n0101","volume":"66","author":"MB Keller","year":"2005","unstructured":"Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66:5\u201312.","journal-title":"J Clin Psychiatry"},{"key":"806_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/NDT.S198774","volume":"16","author":"D Voineskos","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221\u201334. https:\/\/doi.org\/10.2147\/NDT.S198774.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"806_CR13","first-page":"167","volume":"80","author":"A Little","year":"2009","unstructured":"Little A. Treatment-resistant depression. Am Fam Physician. 2009;80:167\u201372.","journal-title":"Am Fam Physician"},{"key":"806_CR14","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1111\/bph.15596","volume":"179","author":"M Papp","year":"2022","unstructured":"Papp M, Cubala WJ, Swiecicki L, Newman-Tancredi A, Willner P. Perspectives for therapy of treatment-resistant depression. Br J Pharmacol. 2022;179:4181\u2013200. https:\/\/doi.org\/10.1111\/bph.15596.","journal-title":"Br J Pharmacol"},{"key":"806_CR15","doi-asserted-by":"publisher","unstructured":"Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N. Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2018;5:CD010558. https:\/\/doi.org\/10.1002\/14651858.CD010558.pub2.","DOI":"10.1002\/14651858.CD010558.pub2"},{"key":"806_CR16","doi-asserted-by":"publisher","first-page":"21759","DOI":"10.3390\/ijms160921759","volume":"16","author":"G Li","year":"2015","unstructured":"Li G, Li G, Tian Y, Zhang Y, Hong Y, Hao Y, et al. A novel ligustrazine derivative T-VA prevents neurotoxicity in differentiated PC12 cells and protects the brain against ischemia injury in MCAO rats. Int J Mol Sci. 2015;16:21759\u201374. https:\/\/doi.org\/10.3390\/ijms160921759. Erratum in: Int J Mol Sci. 2016;17:468. https:\/\/doi.org\/10.3390\/ijms17040468. Li, Guoling [corrected to Li, Guoliang].","journal-title":"Int J Mol Sci"},{"key":"806_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.psychres.2018.07.020","volume":"268","author":"JM Li","year":"2018","unstructured":"Li JM, Zhang Y, Su WJ, Liu LL, Gong H, Peng W, et al. Cognitive behavioral therapy for treatment-resistant depression: a systematic review and meta-analysis. Psychiatry Res. 2018;268:243\u201350. https:\/\/doi.org\/10.1016\/j.psychres.2018.07.020.","journal-title":"Psychiatry Res"},{"key":"806_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1159\/000350094","volume":"31","author":"UE Lang","year":"2013","unstructured":"Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31:761\u201377. https:\/\/doi.org\/10.1159\/000350094.","journal-title":"Cell Physiol Biochem"},{"key":"806_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22:394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120.","journal-title":"World Psychiatry"},{"key":"806_CR20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41380-021-01381-x","volume":"27","author":"L Sforzini","year":"2022","unstructured":"Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, et al. A delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry. 2022;27:1286\u201399. https:\/\/doi.org\/10.1038\/s41380-021-01381-x.","journal-title":"Mol Psychiatry"},{"key":"806_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12991-023-00478-7","volume":"22","author":"G Maina","year":"2023","unstructured":"Maina G, Adami M, Ascione G, Bondi E, De Berardis D, Delmonte D, et al. Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel. Ann Gen Psychiatry. 2023;22:48. https:\/\/doi.org\/10.1186\/s12991-023-00478-7.","journal-title":"Ann Gen Psychiatry"},{"key":"806_CR22","doi-asserted-by":"publisher","first-page":"104553","DOI":"10.1016\/j.jbi.2023.104553","volume":"148","author":"G Lombardo","year":"2023","unstructured":"Lombardo G, Couvert C, Kose M, Begum A, Spiertz C, Worrell C, et al. Electronic health records (EHRs) in clinical research and platform trials: application of the innovative EHR-based methods developed by EU-PEARL. J Biomed Inf. 2023;148:104553. https:\/\/doi.org\/10.1016\/j.jbi.2023.104553.","journal-title":"J Biomed Inf"},{"key":"806_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamapsychiatry.2017.0967","volume":"74","author":"DL Fogelson","year":"2017","unstructured":"Fogelson DL, Leuchter A. Defining treatment-resistant depression. JAMA Psychiarty. 2017;74:758\u201359. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0967.","journal-title":"JAMA Psychiarty"},{"key":"806_CR24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41386-021-01059-6","volume":"46","author":"C Fabbri","year":"2021","unstructured":"Fabbri C, Pain O, Hagenaars SP, Lewis CM, Serretti A. Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. Neuropsychopharmacology. 2021;46:1821\u201329. https:\/\/doi.org\/10.1038\/s41386-021-01059-6.","journal-title":"Neuropsychopharmacology"},{"key":"806_CR25","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.2147\/NDT.S264799","volume":"16","author":"C Han","year":"2020","unstructured":"Han C, Wang G, Chan S, Kato T, Ng CH, Tan W, et al. Definition and identification of patients with treatment-resistant depression in real-world clinical practice settings across asia. Neuropsychiatr Dis Treat. 2020;16:2929\u201341. https:\/\/doi.org\/10.2147\/NDT.S264799.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"806_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/0269881111431748","volume":"26","author":"TE Schlaepfer","year":"2012","unstructured":"Schlaepfer TE, Agren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, et al. The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol. 2012;26:587\u2013602. https:\/\/doi.org\/10.1177\/0269881111431748.","journal-title":"J Psychopharmacol"},{"key":"806_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/da.22968","volume":"37","author":"BN Gaynes","year":"2020","unstructured":"Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37:134\u201345. https:\/\/doi.org\/10.1002\/da.22968.","journal-title":"Depress Anxiety"},{"key":"806_CR28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/brainsci12070940","volume":"12","author":"T Gkesoglou","year":"2022","unstructured":"Gkesoglou T, Bargiota SI, Iordanidou E, Vasiliadis M, Bozikas VP, Agorastos A. Prognostic significance of blood-based baseline biomarkers in treatment-resistant depression: a literature review of available studies on treatment response. Brain Sci. 2022;12:940. https:\/\/doi.org\/10.3390\/brainsci12070940.","journal-title":"Brain Sci"},{"key":"806_CR29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jad.2024.01.165","volume":"350","author":"S Vestring","year":"2024","unstructured":"Vestring S, Galuba V, Kern E, Voita S, Berens F, Nasiri D, et al. Ketamine in multiple treatment-resistant depressed inpatients: a naturalistic cohort study. J Affect Disord. 2024;350:895\u201399. https:\/\/doi.org\/10.1016\/j.jad.2024.01.165.","journal-title":"J Affect Disord"},{"key":"806_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.18553\/jmcp.2019.25.7.823","volume":"25","author":"M Sussman","year":"2019","unstructured":"Sussman M, O\u2019sullivan AK, Shah A, Olfson M, Menzin J. Economic burden of treatment-resistant depression on the U.S. Health Care (don Mills) System. J Manag Care Spec Pharm. 2019;25:823\u201335. https:\/\/doi.org\/10.18553\/jmcp.2019.25.7.823.","journal-title":"Health Care (don Mills) System. J Manag Care Spec Pharm"},{"key":"806_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.22365\/jpsych.2021.046","volume-title":"Psychiatriki","author":"C Touloumis","year":"2021","unstructured":"Touloumis C. The burden and the challenge of treatment-resistant depression. In: Psychiatriki. Vol. 32. English, Greek, Modern; 2021. p. 11\u201314. https:\/\/doi.org\/10.22365\/jpsych.2021.046."},{"issue":"396","key":"806_CR32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"2020","author":"GBD","year":"2019","unstructured":"GBD. Diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2019;2020(396):1204\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9. Erratum in: Lancet. 2020;396:1562. https:\/\/doi.org\/10.1016\/S0140-6736(20)32226-1.","journal-title":"Lancet"},{"key":"806_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1017\/S0033291722001179","volume":"52","author":"JF Goldberg","year":"2022","unstructured":"Goldberg JF, Nasrallah HA. Major depression is a serious and potentially fatal brain syndrome requiring pharmacotherapy or neuromodulation, and psychotherapy. Psychol Med. 2022;52:1423\u201325. https:\/\/doi.org\/10.1017\/S0033291722001179.","journal-title":"Psychol Med"},{"key":"806_CR34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/wps.20996","volume":"21","author":"R Cf 3rd","year":"2022","unstructured":"Reynolds CF 3rd, Jeste DV, Sachdev PS, Blazer DG. Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry. 2022;21:336\u201363. https:\/\/doi.org\/10.1002\/wps.20996.","journal-title":"World Psychiatry"},{"key":"806_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","volume":"20","author":"L Bartova","year":"2019","unstructured":"Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, et al. Results of the European group for the study of resistant depression (GSRD) - basis for further research and clinical practice. World J Biol Psychiatry. 2019;20:427\u201348. https:\/\/doi.org\/10.1080\/15622975.2019.1635270.","journal-title":"World J Biol Psychiatry"},{"key":"806_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jad.2020.07.045","volume":"277","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Millson B, Power GS. Burden of treatment resistant depression (TRD) in patients with major depressive disorder in Ontario using institute for clinical evaluative sciences (ices) databases: economic burden and healthcare resource utilization. J Affect Disord. 2020;277:30\u201338. https:\/\/doi.org\/10.1016\/j.jad.2020.07.045.","journal-title":"J Affect Disord"},{"key":"806_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.2018.233","volume":"214","author":"R Strawbridge","year":"2019","unstructured":"Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry. 2019;214:42\u201351. https:\/\/doi.org\/10.1192\/bjp.2018.233.","journal-title":"Br J Psychiatry"},{"key":"806_CR38","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bph.15753","volume":"179","author":"\u00c9 Borb\u00e9ly","year":"2022","unstructured":"Borb\u00e9ly \u00c9, Simon M, Fuchs E, Wiborg O, Cz\u00e9h B, Helyes Z. Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol. 2022;179:1146\u201386. https:\/\/doi.org\/10.1111\/bph.15753.","journal-title":"Br J Pharmacol"},{"key":"806_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","volume":"17","author":"DF Ionescu","year":"2015","unstructured":"Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17:111\u201326. https:\/\/doi.org\/10.31887\/DCNS.2015.17.2\/dionescu.","journal-title":"Dialogues Clin Neurosci"},{"key":"806_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2018.04.016","volume":"235","author":"IO Bergfeld","year":"2018","unstructured":"Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362\u201367. https:\/\/doi.org\/10.1016\/j.jad.2018.04.016.","journal-title":"J Affect Disord"},{"key":"806_CR41","doi-asserted-by":"publisher","first-page":"120095","DOI":"10.1016\/j.jns.2021.120095","volume":"434","author":"S Subramanian","year":"2022","unstructured":"Subramanian S, Lopez R, Zorumski CF, Cristancho P. Electroconvulsive therapy in treatment resistant depression. J Neurol Sci. 2022;434:120095. https:\/\/doi.org\/10.1016\/j.jns.2021.120095.","journal-title":"J Neurol Sci"},{"key":"806_CR42","doi-asserted-by":"publisher","first-page":"152156","DOI":"10.1016\/j.comppsych.2019.152156","volume":"98","author":"JM Bottomley","year":"2019","unstructured":"Bottomley JM, LeReun C, Diamantopoulos A, Mitchell S, Gaynes BN. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: a systematic review and meta-analysis. Compr Psychiatry. 2019;98:152156. https:\/\/doi.org\/10.1016\/j.comppsych.2019.152156.","journal-title":"Compr Psychiatry"},{"key":"806_CR43","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.brs.2021.08.010","volume":"14","author":"Z Zhu","year":"2021","unstructured":"Zhu Z, Hubbard E, Guo X, Barbosa DAN, Popal AM, Cai C, et al. A connectomic analysis of deep brain stimulation for treatment-resistant depression. Brain Stimul. 2021;14:1226\u201333. https:\/\/doi.org\/10.1016\/j.brs.2021.08.010.","journal-title":"Brain Stimul"},{"key":"806_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.brs.2019.08.013","volume":"13","author":"PB Fitzgerald","year":"2020","unstructured":"Fitzgerald PB, Chen L, Richardson K, Daskalakis ZJ, Hoy KE. A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression. Brain Stimul. 2020;13:137\u201344. https:\/\/doi.org\/10.1016\/j.brs.2019.08.013.","journal-title":"Brain Stimul"},{"key":"806_CR45","doi-asserted-by":"publisher","first-page":"1291176","DOI":"10.3389\/fpsyt.2023.1291176","volume":"14","author":"E Mancuso","year":"2023","unstructured":"Mancuso E, Sampogna G, Boiano A, Della Rocca B, Di Vincenzo M, Lapadula MV, et al. Biological correlates of treatment resistant depression: a review of peripheral biomarkers. Front Psychiatry. 2023;14:1291176. https:\/\/doi.org\/10.3389\/fpsyt.2023.1291176.","journal-title":"Front Psychiatry"},{"key":"806_CR46","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/wps.20906","volume":"20","author":"TA Furukawa","year":"2021","unstructured":"Furukawa TA, Shinohara K, Sahker E, Karyotaki E, Miguel C, Ciharova M, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry. 2021;20:387\u201396. https:\/\/doi.org\/10.1002\/wps.20906.","journal-title":"World Psychiatry"},{"key":"806_CR47","doi-asserted-by":"publisher","first-page":"4176825","DOI":"10.1155\/2017\/4176825","volume":"2017","author":"JA Murphy","year":"2017","unstructured":"Murphy JA, Sarris J, Byrne GJ. A review of the conceptualisation and risk factors associated with treatment-resistant depression. Depress Res Treat. 2017;2017:4176825. https:\/\/doi.org\/10.1155\/2017\/4176825.","journal-title":"Depress Res Treat"},{"key":"806_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/ijms17030381","volume":"17","author":"SW Jeon","year":"2016","unstructured":"Jeon SW, Kim YK. Molecular neurobiology and promising new treatment in depression. Int J Mol Sci. 2016;17:381. https:\/\/doi.org\/10.3390\/ijms17030381.","journal-title":"Int J Mol Sci"},{"key":"806_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/cphy.c150015","volume":"6","author":"JP Herman","year":"2016","unstructured":"Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response. Compr Physiol. 2016;6:603\u201321. https:\/\/doi.org\/10.1002\/cphy.c150015.","journal-title":"Compr Physiol"},{"key":"806_CR50","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.3390\/cells12232726","volume":"12","author":"E Knezevic","year":"2023","unstructured":"Knezevic E, Nenic K, Milanovic V, Knezevic NN. The role of cortisol in chronic stress, neurodegenerative diseases, and psychological disorders. Cells. 2023;12:2726. https:\/\/doi.org\/10.3390\/cells12232726.","journal-title":"Cells"},{"key":"806_CR51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00213-010-2151-x","volume":"214","author":"NR Nugent","year":"2011","unstructured":"Nugent NR, Tyrka AR, Carpenter LL, Price LH. Gene-environment interactions: early life stress and risk for depressive and anxiety disorders. Psychopharmacol (berl). 2011;214:175\u201396. https:\/\/doi.org\/10.1007\/s00213-010-2151-x.","journal-title":"Psychopharmacol (berl)"},{"key":"806_CR52","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2174\/1570159X21666230811141557","volume":"22","author":"A Menke","year":"2024","unstructured":"Menke A. The HPA axis as target for depression. Curr Neuropharmacol. 2024;22:904\u201315. https:\/\/doi.org\/10.2174\/1570159X21666230811141557.","journal-title":"Curr Neuropharmacol"},{"key":"806_CR53","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/cells12081178","volume":"12","author":"F Jovanovic","year":"2023","unstructured":"Jovanovic F, Jovanovic V, Knezevic NN. Glucocorticoid hormones as modulators of the kynurenine pathway in chronic pain conditions. Cells. 2023;12:1178. https:\/\/doi.org\/10.3390\/cells12081178.","journal-title":"Cells"},{"key":"806_CR54","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/cells10061548","volume":"10","author":"MN Mithaiwala","year":"2021","unstructured":"Mithaiwala MN, Santana-Coelho D, Porter GA, O\u2019Connor JC. Neuroinflammation and the Kynurenine Pathway in CNS disease: molecular mechanisms and therapeutic implications. Cells. 2021;10:1548. https:\/\/doi.org\/10.3390\/cells10061548.","journal-title":"Cells"},{"key":"806_CR55","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1176\/appi.ajp.2011.10111577","volume":"168","author":"P Zimmermann","year":"2011","unstructured":"Zimmermann P, Br\u00fcckl T, Nocon A, Pfister H, Binder EB, Uhr M, et al. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry. 2011;168:1107\u201316. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10111577.","journal-title":"Am J Psychiatry"},{"key":"806_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/gbb.12026","volume":"12","author":"A Menke","year":"2013","unstructured":"Menke A, Klengel T, Rubel J, Br\u00fcckl T, Pfister H, Lucae S, et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav. 2013;12:289\u201396. https:\/\/doi.org\/10.1111\/gbb.12026.","journal-title":"Genes Brain Behav"},{"key":"806_CR57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.yebeh.2013.10.020","volume":"38","author":"MF Juruena","year":"2014","unstructured":"Juruena MF. Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav. 2014;38:148\u201359. https:\/\/doi.org\/10.1016\/j.yebeh.2013.10.020.","journal-title":"Epilepsy Behav"},{"key":"806_CR58","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fpsyt.2019.00423","volume":"10","author":"AJ Perrin","year":"2019","unstructured":"Perrin AJ, Horowitz MA, Roelofs J, Zunszain PA, Pariante CM. Glucocorticoid resistance: is it a requisite for increased cytokine production in depression? A systematic review and meta-analysis. Front Psychiatry. 2019;10:423. https:\/\/doi.org\/10.3389\/fpsyt.2019.00423.","journal-title":"Front Psychiatry"},{"key":"806_CR59","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.biopsych.2018.09.031","volume":"85","author":"EL Belleau","year":"2019","unstructured":"Belleau EL, Treadway MT, Pizzagalli DA. The impact of stress and Major depressive disorder on hippocampal and medial prefrontal cortex morphology. Biol Psychiatry. 2019;85:443\u201353. https:\/\/doi.org\/10.1016\/j.biopsych.2018.09.031.","journal-title":"Biol Psychiatry"},{"key":"806_CR60","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1134\/S0022093024040203","volume":"60","author":"NV Gulyaeva","year":"2024","unstructured":"Gulyaeva NV. Augmented cortisol and antiglucocorticoid therapy in mood disorders: the hippocampus as a potential drug target. J Evol Biochem Phys. 2024;60:1516\u201330. https:\/\/doi.org\/10.1134\/S0022093024040203.","journal-title":"J Evol Biochem Phys"},{"key":"806_CR61","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/brainsci11101298","volume":"11","author":"J Mikulska","year":"2021","unstructured":"Mikulska J, Juszczyk G, Gawro\u0144ska-Grzywacz M, Herbet M. HPA axis in the Pathomechanism of Depression and schizophrenia: new therapeutic strategies based on its participation. Brain Sci. 2021;11:1298. https:\/\/doi.org\/10.3390\/brainsci11101298.","journal-title":"Brain Sci"},{"key":"806_CR62","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41398-021-01343-5","volume":"11","author":"K Markopoulou","year":"2021","unstructured":"Markopoulou K, Fischer S, Papadopoulos A, Poon L, Rane LJ, Fekadu A, et al. Comparison of hypothalamo-pituitary-adrenal function in treatment resistant unipolar and bipolar depression. Transl Psychiatry. 2021;11:244. https:\/\/doi.org\/10.1038\/s41398-021-01343-5.","journal-title":"Transl Psychiatry"},{"key":"806_CR63","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s12325-017-0621-9","volume":"34","author":"D Nguyen","year":"2017","unstructured":"Nguyen D, Mizne S. Effects of Ketoconazole on the pharmacokinetics of Mifepristone, a competitive glucocorticoid receptor antagonist, in healthy men. Adv Ther. 2017;34:2371\u201385. https:\/\/doi.org\/10.1007\/s12325-017-0621-9.","journal-title":"Adv Ther"},{"key":"806_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jpsychires.2010.10.005","volume":"45","author":"HC Abercrombie","year":"2011","unstructured":"Abercrombie HC, Jahn AL, Davidson RJ, Kern S, Kirschbaum C, Halverson J. Cortisol\u2019s effects on hippocampal activation in depressed patients are related to alterations in memory formation. J Psychiatr Res. 2011;45:15\u201323. https:\/\/doi.org\/10.1016\/j.jpsychires.2010.10.005.","journal-title":"J Psychiatr Res"},{"key":"806_CR65","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1196\/annals.1364.037","volume":"1071","author":"R Brunner","year":"2006","unstructured":"Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S. Effect of high-dose cortisol on memory functions. Ann N Y Acad Sci. 2006;1071:434\u201337. https:\/\/doi.org\/10.1196\/annals.1364.037.","journal-title":"Ann N Y Acad Sci"},{"key":"806_CR66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bbi.2020.01.011","volume":"87","author":"Y Sun","year":"2020","unstructured":"Sun Y, Drevets W, Turecki G, Li QS. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine. Brain Behav Immun. 2020;87:404\u201312. https:\/\/doi.org\/10.1016\/j.bbi.2020.01.011.","journal-title":"Brain Behav Immun"},{"key":"806_CR67","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jad.2023.07.078","volume":"339","author":"W Ou","year":"2023","unstructured":"Ou W, Chen Y, Ju Y, Ma M, Qin Y, Bi Y, et al. The kynurenine pathway in major depressive disorder under different disease states: a systematic review and meta-analysis. J Affect Disord. 2023;339:624\u201332. https:\/\/doi.org\/10.1016\/j.jad.2023.07.078.","journal-title":"J Affect Disord"},{"key":"806_CR68","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/ndt\/gfaa200","volume":"35","author":"M Hilderman","year":"2020","unstructured":"Hilderman M, Bruchfeld A. The cholinergic anti-inflammatory pathway in chronic kidney disease-review and vagus nerve stimulation clinical pilot study. Nephrol Dial Transpl. 2020;35:1840\u201352. https:\/\/doi.org\/10.1093\/ndt\/gfaa200.","journal-title":"Nephrol Dial Transpl"},{"key":"806_CR69","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.psyneuen.2018.05.013","volume":"94","author":"N Michels","year":"2018","unstructured":"Michels N, Clarke G, Olavarria-Ramirez L, G\u00f3mez-Mart\u00ednez S, D\u00edaz LE, Marcos A, et al. Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: a cross-sectional analysis of two cohorts. Psychoneuroendocrinology. 2018;94:104\u201311. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.05.013.","journal-title":"Psychoneuroendocrinology"},{"key":"806_CR70","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1176\/appi.neuropsych.15030053","volume":"28","author":"GE Tafet","year":"2016","unstructured":"Tafet GE, Nemeroff CB. The links between stress and depression: psychoneuroendocrinological, genetic, and environmental interactions. J Neuropsychiatry Clin Neurosci. 2016;28:77\u201388. https:\/\/doi.org\/10.1176\/appi.neuropsych.15030053.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"806_CR71","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12974-014-0151-1","volume":"11","author":"DJ Allison","year":"2014","unstructured":"Allison DJ, Ditor DS. The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. J Neuroinflammation. 2014;11:151. https:\/\/doi.org\/10.1186\/s12974-014-0151-1.","journal-title":"J Neuroinflammation"},{"key":"806_CR72","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fpsyt.2015.00116","volume":"6","author":"JM Parrott","year":"2015","unstructured":"Parrott JM, O\u2019Connor JC. Kynurenine 3-monooxygenase: an influential Mediator of neuropathology. Front Psychiatry. 2015;6:116. https:\/\/doi.org\/10.3389\/fpsyt.2015.00116.","journal-title":"Front Psychiatry"},{"key":"806_CR73","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/da.20589","volume":"26","author":"S Akhondzadeh","year":"2009","unstructured":"Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26:607\u201311. https:\/\/doi.org\/10.1002\/da.20589.","journal-title":"Depress Anxiety"},{"key":"806_CR74","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s12640-019-9997-4","volume":"35","author":"G Castellano-Gonzalez","year":"2019","unstructured":"Castellano-Gonzalez G, Jacobs KR, Don E, Cole NJ, Adams S, Lim CK, et al. Kynurenine 3-monooxygenase activity in human primary neurons and effect on cellular bioenergetics identifies new neurotoxic mechanisms. Neurotox Res. 2019;35:530\u201341. https:\/\/doi.org\/10.1007\/s12640-019-9997-4.","journal-title":"Neurotox Res"},{"key":"806_CR75","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2016","unstructured":"Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22\u201334. https:\/\/doi.org\/10.1038\/nri.2015.5.","journal-title":"Nat Rev Immunol"},{"key":"806_CR76","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1073\/pnas.1118355109","volume":"109","author":"S Cohen","year":"2012","unstructured":"Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A. 2012;109:5995\u201399. https:\/\/doi.org\/10.1073\/pnas.1118355109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"806_CR77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.psyneuen.2008.08.004","volume":"34","author":"K Markopoulou","year":"2009","unstructured":"Markopoulou K, Papadopoulos A, Juruena MF, Poon L, Pariante CM, Cleare AJ. The ratio of cortisol\/DHEA in treatment resistant depression. Psychoneuroendocrinology. 2009;34:19\u201326. https:\/\/doi.org\/10.1016\/j.psyneuen.2008.08.004.","journal-title":"Psychoneuroendocrinology"},{"key":"806_CR78","doi-asserted-by":"publisher","first-page":"1182345","DOI":"10.3389\/fpsyt.2023.1182345","volume":"14","author":"M Malekpour","year":"2023","unstructured":"Malekpour M, Shekouh D, Safavinia ME, Shiralipour S, Jalouli M, Mortezanejad S, et al. Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery. Front Psychiatry. 2023;14:1182345. https:\/\/doi.org\/10.3389\/fpsyt.2023.1182345.","journal-title":"Front Psychiatry"},{"key":"806_CR79","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tins.2008.06.006","volume":"31","author":"CM Pariante","year":"2008","unstructured":"Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31:464\u201368. https:\/\/doi.org\/10.1016\/j.tins.2008.06.006.","journal-title":"Trends Neurosci"},{"key":"806_CR80","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.pnpbp.2018.10.010","volume":"89","author":"BW Dunlop","year":"2019","unstructured":"Dunlop BW, Wong A. The hypothalamic-pituitary-adrenal axis in PTSD: pathophysiology and treatment interventions. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:361\u201379. https:\/\/doi.org\/10.1016\/j.pnpbp.2018.10.010.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"806_CR81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/jpm11020155","volume":"11","author":"A Halaris","year":"2021","unstructured":"Halaris A, Sohl E, Whitham EA. Treatment-resistant depression revisited: a glimmer of hope. J Pers Med. 2021;11:155. https:\/\/doi.org\/10.3390\/jpm11020155.","journal-title":"J Pers Med"},{"key":"806_CR82","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1476-5381.2011.01557.x","volume":"165","author":"FE O\u2019Brien","year":"2012","unstructured":"O\u2019Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2012;165:289\u2013312. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01557.x.","journal-title":"Br J Pharmacol"},{"key":"806_CR83","doi-asserted-by":"publisher","first-page":"105080","DOI":"10.1016\/j.nbd.2020.105080","volume":"145","author":"van Vliet Ea","year":"2020","unstructured":"van Vliet Ea, Ndode-Ekane XE, Lehto LJ, Gorter JA, Andrade P, Aronica E, et al. Long-lasting blood-brain barrier dysfunction and neuroinflammation after traumatic brain injury. Neurobiol Dis. 2020;145:105080. https:\/\/doi.org\/10.1016\/j.nbd.2020.105080.","journal-title":"Neurobiol Dis"},{"key":"806_CR84","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/biom15040502","volume":"15","author":"A S\u0103lcudean","year":"2025","unstructured":"S\u0103lcudean A, Bodo CR, Popovici RA, Cozma MM, P\u0103curar M, Cr\u0103ciun RE, et al. Neuroinflammation-A crucial Factor in the pathophysiology of Depression-A comprehensive review. Biomolecules. 2025;15:502. https:\/\/doi.org\/10.3390\/biom15040502.","journal-title":"Biomolecules"},{"key":"806_CR85","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1177\/02698811211026426","volume":"35","author":"E Kopra","year":"2021","unstructured":"Kopra E, Mondelli V, Pariante C, Nikkheslat N. Ketamine\u2019s effect on inflammation and kynurenine pathway in depression: a systematic review. J Psychopharmacol. 2021;35:934\u201345. https:\/\/doi.org\/10.1177\/02698811211026426.","journal-title":"J Psychopharmacol"},{"key":"806_CR86","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/1871527316666170413110605","volume":"16","author":"G Serafini","year":"2017","unstructured":"Serafini G, Adavastro G, Canepa G, Capobianco L, Conigliaro C, Pittaluga F, et al. Abnormalities in Kynurenine pathway metabolism in treatment-resistant depression and suicidality: a systematic review. CNS Neurol Disord Drug Targets. 2017;16:440\u201353. https:\/\/doi.org\/10.2174\/1871527316666170413110605.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"806_CR87","doi-asserted-by":"publisher","first-page":"107037","DOI":"10.1016\/j.psyneuen.2024.107037","volume":"165","author":"F Duval","year":"2024","unstructured":"Duval F, Mokrani MC, Danila V, Weiss T, Lopera FG, Tomsa M. Hypothalamic-pituitary-adrenal axis hyperactivity is normalized after successful intermittent theta-burst stimulation in resistant depressed patients. Psychoneuroendocrinology. 2024;165:107037. https:\/\/doi.org\/10.1016\/j.psyneuen.2024.107037.","journal-title":"Psychoneuroendocrinology"},{"key":"806_CR88","doi-asserted-by":"publisher","first-page":"102538","DOI":"10.1016\/j.npep.2025.102538","volume":"112","author":"P Singanwad","year":"2025","unstructured":"Singanwad P, Tatode A, Qutub M, Taksande B, Umekar M, Trivedi R, et al. Neuropeptide Y as a multifaceted modulator of neuroplasticity, neuroinflammation, and HPA axis dysregulation: perceptions into treatment-resistant depression. Neuropeptides. 2025;112:102538. https:\/\/doi.org\/10.1016\/j.npep.2025.102538.","journal-title":"Neuropeptides"},{"key":"806_CR89","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41398-024-03055-y","volume":"14","author":"A Inserra","year":"2024","unstructured":"Inserra A, Campanale A, Rezai T, Romualdi P, Rubino T. Epigenetic mechanisms of rapid-acting antidepressants. Transl Psychiatry. 2024;14:359. https:\/\/doi.org\/10.1038\/s41398-024-03055-y.","journal-title":"Transl Psychiatry"},{"key":"806_CR90","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.3390\/molecules25225294","volume":"25","author":"Y Zorkina","year":"2020","unstructured":"Zorkina Y, Abramova O, Ushakova V, Morozova A, Zubkov E, Valikhov M, et al. Nano Carrier Drug delivery Systems for the treatment of neuropsychiatric disorders: advantages and limitations. Molecules. 2020;25:5294. https:\/\/doi.org\/10.3390\/molecules25225294.","journal-title":"Molecules"},{"key":"806_CR91","doi-asserted-by":"publisher","first-page":"1196235","DOI":"10.3389\/fpsyt.2023.1196235","volume":"14","author":"Y Hakamata","year":"2023","unstructured":"Hakamata Y, Hori H, Mizukami S, Izawa S, Yoshida F, Moriguchi Y, et al. Blunted diurnal interleukin-6 rhythm is associated with amygdala emotional hyporeactivity and depression: a modulating role of gene-stressor interactions. Front Psychiatry. 2023;14:1196235. https:\/\/doi.org\/10.3389\/fpsyt.2023.1196235.","journal-title":"Front Psychiatry"},{"key":"806_CR92","doi-asserted-by":"publisher","first-page":"105926","DOI":"10.1016\/j.nbd.2022.105926","volume":"175","author":"EM Medina-Rodriguez","year":"2022","unstructured":"Medina-Rodriguez EM, Beurel E. Blood brain barrier and inflammation in depression. Neurobiol Dis. 2022;175:105926. https:\/\/doi.org\/10.1016\/j.nbd.2022.105926.","journal-title":"Neurobiol Dis"},{"key":"806_CR93","doi-asserted-by":"publisher","first-page":"176967","DOI":"10.1016\/j.ejphar.2024.176967","volume":"983","author":"S Hall","year":"2024","unstructured":"Hall S, Parr BA, Hussey S, Anoopkumar-Dukie S, Arora D, Grant GD. The neurodegenerative hypothesis of depression and the influence of antidepressant medications. Eur J Pharmacol. 2024;983:176967. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176967.","journal-title":"Eur J Pharmacol"},{"key":"806_CR94","doi-asserted-by":"publisher","first-page":"2225800","DOI":"10.1080\/14756366.2023.2225800","volume":"38","author":"P Chen","year":"2023","unstructured":"Chen P, Geng X. Research progress on the kynurenine pathway in the prevention and treatment of Parkinson\u2019s disease. J Enzym Inhib Med Chem. 2023;38:2225800. https:\/\/doi.org\/10.1080\/14756366.2023.2225800.","journal-title":"J Enzym Inhib Med Chem"},{"key":"806_CR95","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.psyneuen.2007.05.002","volume":"32","author":"C Heesen","year":"2007","unstructured":"Heesen C, Gold SM, Huitinga I, Reul JM. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review. Psychoneuroendocrinology. 2007;32:604\u201318. https:\/\/doi.org\/10.1016\/j.psyneuen.2007.05.002.","journal-title":"Psychoneuroendocrinology"},{"key":"806_CR96","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1017\/S1461145713000692","volume":"16","author":"FE O\u2019Brien","year":"2013","unstructured":"O\u2019Brien FE, Clarke G, Dinan TG, Cryan JF, Griffin BT. Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. Int J Neuropsychopharmacol. 2013;16:2259\u201372. https:\/\/doi.org\/10.1017\/S1461145713000692.","journal-title":"Int J Neuropsychopharmacol"},{"key":"806_CR97","doi-asserted-by":"publisher","first-page":"14667","DOI":"10.3390\/ijms232314667","volume":"23","author":"AB Chai","year":"2022","unstructured":"Chai AB, Callaghan R, Gelissen IC. Regulation of P-Glycoprotein in the brain. Int J Mol Sci. 2022;23:14667. https:\/\/doi.org\/10.3390\/ijms232314667.","journal-title":"Int J Mol Sci"},{"key":"806_CR98","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00702-022-02553-x","volume":"129","author":"NS Yilmaz","year":"2022","unstructured":"Yilmaz NS, Sen B, Karadag RF, Aslan S, Ekmekci Ertek I, Bozkurt A, et al. A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response: a pilot study. J Neural Transm (vienna). 2022;129:1513\u201326. https:\/\/doi.org\/10.1007\/s00702-022-02553-x. Erratum in: J Neural Transm (Vienna). 2023;130:1315. https:\/\/doi.org\/10.1007\/s00702-022-02573-7.","journal-title":"J Neural Transm (vienna)"},{"key":"806_CR99","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nn.4489","volume":"20","author":"K Kisler","year":"2017","unstructured":"Kisler K, Nelson AR, Rege SV, Ramanathan A, Wang Y, Ahuja A, et al. Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat Neurosci. 2017;20:406\u201316. https:\/\/doi.org\/10.1038\/nn.4489.","journal-title":"Nat Neurosci"},{"key":"806_CR100","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1298\/ptr.R0008","volume":"23","author":"H Sato","year":"2020","unstructured":"Sato H. Postural deformity in children with cerebral palsy: why it occurs and how is it managed. Phys Ther Res. 2020;23:8\u201314. https:\/\/doi.org\/10.1298\/ptr.R0008.","journal-title":"Phys Ther Res"},{"key":"806_CR101","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.nut.2013.11.009","volume":"30","author":"L Frommelt","year":"2014","unstructured":"Frommelt L, Bielohuby M, Menhofer D, Stoehr BJ, Bidlingmaier M, Kienzle E. Effects of low carbohydrate diets on energy and nitrogen balance and body composition in rats depend on dietary protein-to-energy ratio. Nutrition. 2014;30:863\u201368. https:\/\/doi.org\/10.1016\/j.nut.2013.11.009.","journal-title":"Nutrition"},{"issue":"Suppl 3","key":"806_CR102","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00586-018-5519-y","volume":"27","author":"VZ Kovari","year":"2018","unstructured":"Kovari VZ, Horvath L. Surgical management of cauda syndrome in third trimester of pregnancy focusing on spinal anesthesia and right lateral positioning during surgery as possible practices. Eur Spine J. 2018;27(Suppl 3):483\u201388. https:\/\/doi.org\/10.1007\/s00586-018-5519-y.","journal-title":"Eur Spine J"},{"key":"806_CR103","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cpt.3478","volume":"117","author":"KA Vekhova","year":"2025","unstructured":"Vekhova KA, Namiot ED, Jonsson J, Schi\u00f6th HB. Ketamine and esketamine in clinical trials: FDA-Approved and emerging indications, trial trends with putative mechanistic explanations. Clin Pharmacol Ther. 2025;117:374\u201386. https:\/\/doi.org\/10.1002\/cpt.3478.","journal-title":"Clin Pharmacol Ther"},{"key":"806_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.03.020","volume":"127","author":"B Peyrovian","year":"2020","unstructured":"Peyrovian B, McIntyre RS, Phan L, Lui LMW, Gill H, Majeed A, et al. Registered clinical trials investigating ketamine for psychiatric disorders. J Psychiatr Res. 2020;127:1\u201312. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.03.020.","journal-title":"J Psychiatr Res"},{"key":"806_CR105","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1192\/bjo.2023.535","volume":"9","author":"MI Husain","year":"2023","unstructured":"Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BDM, et al. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open. 2023;9:e134. https:\/\/doi.org\/10.1192\/bjo.2023.535.","journal-title":"BJPsych Open"},{"key":"806_CR106","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","volume":"48","author":"GM Goodwin","year":"2023","unstructured":"Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48:1492\u201399. https:\/\/doi.org\/10.1038\/s41386-023-01648-7.","journal-title":"Neuropsychopharmacology"},{"key":"806_CR107","doi-asserted-by":"publisher","first-page":"1244289","DOI":"10.3389\/fpsyt.2023.1244289","volume":"14","author":"XJ Lan","year":"2023","unstructured":"Lan XJ, Yang XH, Qin ZJ, Cai DB, Liu QM, Mai JX, et al. Efficacy and safety of intermittent theta burst stimulation versus high-frequency repetitive transcranial magnetic stimulation for patients with treatment-resistant depression: a systematic review. Front Psychiatry. 2023;14:1244289. https:\/\/doi.org\/10.3389\/fpsyt.2023.1244289.","journal-title":"Front Psychiatry"},{"key":"806_CR108","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41398-020-00901-7","volume":"10","author":"A Karabatsiakis","year":"2020","unstructured":"Karabatsiakis A, Sch\u00f6nfeldt-Lecuona C. Depression, mitochondrial bioenergetics, and electroconvulsive therapy: a new approach towards personalized medicine in psychiatric treatment - a short review and current perspective. Transl Psychiatry. 2020;10:226. https:\/\/doi.org\/10.1038\/s41398-020-00901-7. Erratum in: Transl Psychiatry. 2020;10:277. https:\/\/doi.org\/10.1038\/s41398-020-00973-5.","journal-title":"Transl Psychiatry"},{"key":"806_CR109","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10863-014-9584-6","volume":"47","author":"NJ Klinedinst","year":"2015","unstructured":"Klinedinst NJ, Regenold WT. A mitochondrial bioenergetic basis of depression. J Bioenerg Biomembr. 2015;47:155\u201371. https:\/\/doi.org\/10.1007\/s10863-014-9584-6.","journal-title":"J Bioenerg Biomembr"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00806-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:35:21Z","timestamp":1773196521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00806-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00806-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that no AI-assisted technologies were used to prepare this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI-assisted writing disclosure"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}